The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 38, No. 1, pp. 54-57. DOI 10.1345/aph.1C477
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verea, M. M
Right arrow Articles by Fonseca, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verea, M. M
Right arrow Articles by Fonseca, E.

OBJETIVO: Comunicar un caso de erupción psoriasiforme inducida por infliximab.

RESUMEN DEL CASO: Una mujer de 46 años con fístula enterocutánea secundaria a enfermedad de Crohn desarrolló placas eritematosas, descamativas y pruriginosas en los codos, las rodillas, las manos y los glúteos tras recibir la segunda y tercera dosis de un tratamiento con infliximab intravenoso. El estudio histopatológico mostró un patrón liquenoide. No aparecieron nuevas lesiones tras suspender el tratamiento con infliximab.

DISCUSIÓN: Se han descrito diversos tipos de reacciones cutáneas secundarias al infliximab, un anticuerpo monoclonal anti-TNF-alfa. No se ha descrito con anterioridad una dermatitis psoriasiforme como reacción cutánea por infliximab, pero existen múltiples comunicaciones sobre dermatitis psoriasiformes secundarias a otros fármacos. Una evaluación objetiva de la causalidad determinó este efecto adverso como probable.

CONCLUSIONES: Se describe un caso manifestado clínicamente como una erupción psoriasiforme y que mostraba una imagen histopatológica de dermatitis liquenoide. Este patrón clínico-patológico disociado de reacción cutánea no ha sido referido con anterioridad como un efecto secundario del tratamiento con infliximab.




This article has been cited by other articles:


Home page
 Arch DermatolHome page
J. Seneschal, S. Lepreux, B. Milpied, T. Schaeverbeke, and A. Taieb
Psoriasiform Eruptions During Anti TNF-{alpha} Treatment: Psoriasis or Not?
Arch Dermatol, December 1, 2007; 143(12): 1593 - 1595.
[Full Text] [PDF]

Home page
 Arch DermatolHome page
G. C. de Gannes, M. Ghoreishi, J. Pope, A. Russell, D. Bell, S. Adams, K. Shojania, M. Martinka, and J. P. Dutz
Psoriasiform Eruptions During Anti TNF-{alpha} Treatment: Psoriasis or Not? Reply
Arch Dermatol, December 1, 2007; 143(12): 1595 - 1595.
[Full Text] [PDF]

Home page
 Arch DermatolHome page
R. Ubriani and A. S. Van Voorhees
Onset of Psoriasis During Treatment With TNF-{alpha} Antagonists: A Report of 3 Cases
Arch Dermatol, February 1, 2007; 143(2): 270 - 272.
[Full Text] [PDF]

Home page
 Adv. Physiol. Educ.Home page
E. Dale, M. Davis, and D. L. Faustman
A role for transcription factor NF-{kappa}B in autoimmunity: possible interactions of genes, sex, and the immune response
Advan Physiol Educ, December 1, 2006; 30(4): 152 - 158.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
C Ritchlin and F Tausk
A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.
Ann Rheum Dis, December 1, 2006; 65(12): 1541 - 1544.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
R Peek, R Scott-Jupp, H Strike, J Clinch, and A V Ramanan
Psoriasis after treatment of juvenile idiopathic arthritis with etanercept
Ann Rheum Dis, September 1, 2006; 65(9): 1259 - 1259.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
S Kary, M Worm, H Audring, D Huscher, M Renelt, H Sorensen, E Stander, U Maass, H Lee, W Sterry, et al.
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor {alpha} antagonists
Ann Rheum Dis, March 1, 2006; 65(3): 405 - 407.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verea, M. M
Right arrow Articles by Fonseca, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verea, M. M
Right arrow Articles by Fonseca, E.

homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.